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Procedure for randomisation
Treatment kits labelled with sequential code, with the content of each code determined and packed from a traditional block randomisation scheme were used. For label codes, block randomisation was performed with blocks 2+2. The block randomisation scheme for labelling and packaging was created by a statistician, and forwarded to the National Pharmacy, Sweden for packaging/labelling and to one (1) dedicated unblinded data manager for setting up the computerized system that applies the minimization algorithm for label code assignment to subjects. Label codes were assigned to subjects using a central computerized system that applies a minimization algorithm to ensure good statistical balance between arms. The system is aware of the treatment arm behind each label code and the available supply at each site, and internally randomises to a treatment arm and then selects, randomly, and reveals a label code matching the treatment arm. Minimization was balancing on the following variables age, sex, weight, HbA1c, and total daily insulin dose, and applies an in-between treatment arms difference of max 4 at study level and max 2 at site level. Statistiska Konsultgruppen performed the randomisation scheme. Sites enrolled participants and assigned the intervention, using the above described computerized system. The statistician who created the block randomisation scheme, the National Pharmacy, and one data manager were unblinded. All study personnel and participants were blinded to treatment. The blind was broken by the data manager after clean file and database lock.
Changes to eligibility criteria
The inclusion/exclusion criteria were changed partly to use more general and conventional cut-offs for variables and partly to facilitate further recruitment. The following changes were made:
Lower limit of HbA1c was changed from 8.0% to 7.8% (64 to 62 mmol/l) on 28 January 2013, and from 7.8% to 7.5% (62 to 58 mmol/l) on 2 April 2013.
Lower limit of C-peptide was changed from 0.2 to 0.15 on 28 January 2013 and from 0.15 to 0.10 nmol/l on 11 July 2013.
Upper limit of calcitonin was changed from 50 ng/l to 14.6 pmol/l on 28 January 2013.
Lower limit of fasting glucose was changed from 7.0 to 6.0 mmol/l on 28 January 2013.
Accepted contraceptive methods were defined from "e.g. oral contraceptive pills and intrauterine device (IUD)" to "accepted methods: oral contraceptive pills, depo provera contraceptive injections, implanted contraceptive, transdermal patch, intrauterine device, vasectomized partner, or abstinence." on 28 January 2013.
Lower limit of BMI was changed from 28 to 27.5 kg/m 2 on 30 January 2013.
Upper age limit was changed from 75 to 80 years on 17 June 2013. 
